Mineralys Therapeutics Presents New Post-Hoc Analysis From Target-HTN Phase 2 Trial Of Lorundrostat In Late-Breaking Poster Session At ASN Kidney Week 2023 Meeting
Mineralys Therapeutics Presents New Post-Hoc Analysis From Target-HTN Phase 2 Trial Of Lorundrostat In Late-Breaking Poster Session At ASN Kidney Week 2023 Meeting
Mineralys Therapeutics 在 2023 年 ASN 腎臟週會議的最新海報發佈會上發佈了 Lorundrostat target-HTN 2 期試驗的新事後分析
– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant hypertension –
— 分析進一步支持肥胖相關失調的醛固酮作爲內分型預測失控或耐藥性高血壓患者對lorundrostat治療的反應增強 —
–Endotype identification from Target-HTN may represent a shift towards targeted, precision-directed therapy for hypertension management in future treatment paradigm –
—通過Target-HTN進行內型鑑定可能代表着在未來的治療模式中向有針對性、精確導向的高血壓管理療法的轉變 —
– Ongoing Advance-HTN trial, first of two pivotal studies, will further characterize hypertensive endotype for enhanced response to lorundrostat treatment –
— 正在進行的 Advance-HTN 試驗是兩項關鍵研究中的第一項，將進一步表徵高血壓內型，以增強對氯硝酸鹽治療的反應 —
RADNOR, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone...
賓夕法尼亞州拉德諾，2023年11月2日（GLOBE NEWSWIR...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。